Targeted Therapies in Pancreatic Cancer—Current Landscape and Future Directions
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 1121
Special Issue Editor
Special Issue Information
Dear Colleagues,
Pancreatic cancer remains one of the most challenging malignancies to treat, with a notoriously low survival rate and often late-stage diagnosis. Recent advancements in targeted therapies offer new hope and opportunities for improved outcomes in this aggressive cancer. By honing in on specific molecular and genetic abnormalities, targeted therapies aim to disrupt cancer progression while minimizing the impact on healthy tissues. This Special Issue, titled "Targeted Therapies in Pancreatic Cancer—Current Landscape and Future Directions", seeks to explore the latest breakthroughs and ongoing research in this dynamic field. We will focus on novel therapeutic targets, including advancements in the inhibitors of KRAS and other oncogenic pathways; the role of immunotherapy; artificial intelligence and its ability to predict sensitivity to targeted agents; and personalized medicine approaches that promise to transform the landscape of pancreatic cancer treatment. Our aim is to bring together insights from leading researchers and clinicians to propel our understanding and treatment of pancreatic cancer in this rapidly evolving landscape of targeted therapies. We invite contributions that discuss innovative therapeutic strategies, novel translational research, breaking clinical trial results, and thoughtful perspectives on the future of pancreatic cancer care.
Dr. Yongwoo Dave Seo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- precision oncology
- targeted therapies
- immunotherapy
- KRAS inhibitors
- novel clinical trial design
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
